Trends of breast cancer incidence and risk factor prevalence over 25 years.

Abstract:

INTRODUCTION:To examine the trends in the prevalence of breast cancer risk factors in relation to breast cancer incidence trends and to explore whether the changes in risk factors differed by ethnicity in Hawaii over a 25-year period. METHODS:We pooled 17 population-based epidemiological studies conducted in Hawaii between 1975 and 2001. The study population of 82,295 women included subjects of Caucasian, Japanese, Native Hawaiian, Chinese, and Filipino ancestry. We computed age-adjusted prevalence estimates by ethnic group for 5-year time periods. Logistic regression was used to evaluate trends over time. RESULTS:The prevalence of an early age at menarche, nulliparity, and parity of fewer than three children, but not that of a late age at first live birth, increased during the study period. Whereas current smoking decreased for all ethnicities over time, the age-adjusted prevalence of overweight, obesity, college education, and alcohol use increased. Trends differed by ethnicity. For Native Hawaiians, the prevalence of overweight, obesity, alcohol use and nulliparity rose over time. For Japanese, the prevalence of overweight, early age at menarche, and having fewer than three children increased. Caucasians showed an increasing prevalence of overweight, obesity, college education, and nulliparity. In Filipina women, we observed changes in reproductive behavior and increasing obesity. CONCLUSIONS:Despite a slowing trend for some breast cancer risk factors, the overall risk profile in this population may lead to further increases in breast cancer incidence. Different ethnic groups may benefit from specific prevention strategies.

authors

Maskarinec G,Zhang Y,Takata Y,Pagano I,Shumay DM,Goodman MT,Le Marchand L,Nomura AM,Wilkens LR,Kolonel LN

doi

10.1007/s10549-005-9129-0

subject

Has Abstract

pub_date

2006-07-01 00:00:00

pages

45-55

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

98

pub_type

杂志文章
  • Clinical significance of angiogenic factors in breast cancer.

    abstract::Growth, progression, and metastasis of breast cancer, as well as of most of the other tumors, are angiogenesis-dependent processes. Several pro-angiogenic growth factors and endogenous inhibitors of angiogenesis have been identified and sequenced, and experimental studies suggest that angiogenic activity of a tumor ma...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1006175504673

    authors: Locopo N,Fanelli M,Gasparini G

    更新日期:1998-01-01 00:00:00

  • Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer.

    abstract::We evaluated the question of whether the chemosensitizers verapamil and quinine given orally to breast cancer patients failing combination chemotherapy alone would result in additional clinical responses. In vitro studies reported here showed verapamil sensitization of Adriamycin resistance in 18.8% of fresh human bre...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1005716214718

    authors: Taylor CW,Dalton WS,Mosley K,Dorr RT,Salmon SE

    更新日期:1997-01-01 00:00:00

  • The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.

    abstract::Breast cancer has been the most common malignant tumor among women in many large cities of China. The aim of this study was to clarify the prognostic significance of serum anti-p53 antibodies (p53 Abs) in Chinese patients of breast cancer. One hundred and forty-four patients with invasive ductal carcinoma of breast we...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-4321-9

    authors: Gao RJ,Bao HZ,Yang Q,Cong Q,Song JN,Wang L

    更新日期:2005-09-01 00:00:00

  • Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum.

    abstract::Screening of a breast cancer cDNA library from SKBR3 human breast cancer cells by SEREX (serological analysis of cDNA expression library) using a preselected serum from a breast cancer patient revealed 13 genes, two of which, INT-MI-1 and INT-MI-2, encode novel gene products, while the remaining 11 genes and their pro...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1015854415746

    authors: Forti S,Scanlan MJ,Invernizzi A,Castiglioni F,Pupa S,Agresti R,Fontanelli R,Morelli D,Old LJ,Pupa SM,Ménard S

    更新日期:2002-06-01 00:00:00

  • Postoperative complications and survival of elderly breast cancer patients: a FOCUS study analysis.

    abstract::Old age is associated with comorbidity and decreased functioning which influences treatment decisions in elderly breast cancer patients. The purpose of this study was to identify risk factors for complications after breast cancer surgery in elderly patients, and to assess mortality in patients with postoperative compl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2462-9

    authors: de Glas NA,Kiderlen M,Bastiaannet E,de Craen AJ,van de Water W,van de Velde CJ,Liefers GJ

    更新日期:2013-04-01 00:00:00

  • Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

    abstract::The development of recombinant vaccines for specific immunotherapy of carcinoma represents a novel approach for the treatment of breast cancer and other tumor types. This article reviews the various parameters that should be considered in the development of recombinant vaccines. Several breast cancer associated antige...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF01803781

    authors: Schlom J,Kantor J,Abrams S,Tsang KY,Panicali D,Hamilton JM

    更新日期:1996-01-01 00:00:00

  • MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.

    abstract:PURPOSE:miRNAs have been linked to chemosensitivity of breast cancer cells in vitro. In patients, however, there is no clinically validated method for predicting chemotherapy response. The aim of this study was to assess whether (I) a specific pattern of miRNA expression in pretherapeutic biopsies can predict response ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4132-9

    authors: Raychaudhuri M,Bronger H,Buchner T,Kiechle M,Weichert W,Avril S

    更新日期:2017-04-01 00:00:00

  • Drug dosage intensity--a panel discussion.

    abstract::There is now widespread interest in the subject of drug dose intensity in cancer treatment. Recent retrospective analyses have shown a clear-cut benefit for those patients receiving either the intended drug dosage in a particular regimen or the highest dosage achievable through an escalation scheme. In this discussion...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01807361

    authors: McGuire WL,Goldie J,Hryniuk W,Tormey DC

    更新日期:1987-01-01 00:00:00

  • The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?

    abstract::The goal of the present study was to evaluate the role of the tyrosine kinase receptor fibroblast growth factor-1 (FGFR1) and its ligand, the fibroblast growth factor 2 (FGF2) in determining the response to chemoradiotherapy of breast cancers. S14 was a phase II neoadjuvant study carried out at the Institut Curie that...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2027-3

    authors: Massabeau C,Sigal-Zafrani B,Belin L,Savignoni A,Richardson M,Kirova YM,Cohen-Jonathan-Moyal E,Mégnin-Chanet F,Hall J,Fourquet A

    更新日期:2012-07-01 00:00:00

  • Ras-related protein 1 and the insulin-like growth factor type I receptor are associated with risk of progression in patients diagnosed with carcinoma in situ.

    abstract::Currently, there are no applied molecular markers to aid in predicting risk of carcinoma in situ (CIS) progression to invasive cancer, and therefore, all women diagnosed with CIS undergo surgery. Standard assessment of protein expression in fixed tissue by immunohistochemistry (IHC) is not quantitative and hence is no...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1227-y

    authors: Furstenau DK,Mitra N,Wan F,Lewis R,Feldman MD,Fraker DL,Guvakova MA

    更新日期:2011-09-01 00:00:00

  • Effects of cyclic adjustment training delivered via a mobile device on psychological resilience, depression, and anxiety in Chinese post-surgical breast cancer patients.

    abstract:PURPOSE:Psychological resilience is an important ability for women with breast cancer to cope effectively with depression and anxiety. However, the demands of long-term hospital-based psychological rehabilitation interventions are not met in mainland China, where shorter hospital stays and longer home rehabilitation ar...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05368-9

    authors: Zhou K,Li J,Li X

    更新日期:2019-11-01 00:00:00

  • Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.

    abstract::Evaluation of cost-utility is critical in assessing the medical utility of predictive or prognostic biomarkers. Current methods involve complex state-transition models, requiring comprehensive data inputs. We propose a simplified decision-analytic tool to explore the relative effect of factors contributing to the cost...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3677-3

    authors: Safonov A,Wang S,Gross CP,Agarwal D,Bianchini G,Pusztai L,Hatzis C

    更新日期:2016-01-01 00:00:00

  • Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race.

    abstract:PURPOSE:To investigate whether treatment (surgery, radiation therapy, and endocrine therapy) contributes to racial disparities in outcomes of ductal carcinoma in situ (DCIS). PATIENTS AND METHODS:The analysis included 8184 non-Hispanic White and 954 non-Hispanic Black women diagnosed with DCIS between 1996 and 2011 an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-4030-6

    authors: Madubata CC,Liu Y,Goodman MS,Yun S,Yu J,Lian M,Colditz GA

    更新日期:2016-12-01 00:00:00

  • National consensus recommendations on patient-centered care for ductal carcinoma in situ.

    abstract:PURPOSE:The purpose of this research was to generate recommendations on strategies to achieve patient-centered care (PCC) for ductal carcinoma in situ (DCIS). METHODS:Thirty clinicians (surgeons, medical/radiation oncologists, radiologists, nurses, navigators) who manage DCIS and 32 DCIS survivors aged 18 or older wer...

    journal_title:Breast cancer research and treatment

    pub_type: 共识发展会议,杂志文章,评审

    doi:10.1007/s10549-019-05132-z

    authors: Gagliardi AR,Wright FC,Look Hong NJ,Groot G,Helyer L,Meiers P,Quan ML,Urquhart R,Warburton R

    更新日期:2019-04-01 00:00:00

  • Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.

    abstract::One of the most efficacious primary therapies in HER2-positive breast cancer was published by the M.D. Anderson group in 2005. This randomized trial evaluated the addition of trastuzumab to a taxane-anthracycline based chemotherapy. Despite largely significant differences in pathological complete response (pCR) in the...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-012-2149-7

    authors: Pernas S,Gil-Gil M,de Olza MO,Gumà A,Climent F,Petit A,Pla MJ,García-Tejedor A,López-Ojeda A,Falo C,Fernandez-Otega A,Mesia C,Pérez-Martin FJ,Urruticoechea A,Germà JR

    更新日期:2012-08-01 00:00:00

  • Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.

    abstract::Targeting HER-2 over-expressing breast cancer cells with trastuzumab has resulted in significant improvements in both disease-free and overall survival rates. However, despite a favorable initial response, some cancer cells become resistant and develop into fatal metastatic disease. Here we report that we can specific...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0828-9

    authors: Zhang KX,Kim C,Chow E,Chen IS,Jia W,Rennie PS

    更新日期:2011-01-01 00:00:00

  • The relationship of urinary and plasma androgens to steroid receptors and menopausal status in breast cancer patients and their influence on survival.

    abstract::The relationships between urinary 11-desoxy-17-oxo steroids (11-DOS), the ratio of 11-DOS to urinary 17-hydroxycorticosteroids (urinary discriminant ratio), plasma levels of the adrenal androgens dehydroepiandrosterone (DHA), DHA sulphate (DHAS), and 7 alpha-hydroxy DHA (7 alpha DHA), and tumour oestrogen receptor (ER...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665771

    authors: Mason BH,Holdaway IM,Skinner SJ,Kay RG

    更新日期:1994-01-01 00:00:00

  • A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer.

    abstract:PURPOSE:To update and expand on data related to treatment, resource utilization, and costs by cancer stage in Canadian patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). METHODS:We analyzed data for adult women diagnosed with invasive HR+/HER2- B...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05960-4

    authors: Brezden-Masley C,Fathers KE,Coombes ME,Pourmirza B,Xue C,Jerzak KJ

    更新日期:2020-10-16 00:00:00

  • Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation.

    abstract::Thirty-eight patients treated for primary breast cancer as part of a prospective randomized clinical trial were questioned retrospectively as to their psychosocial adaptation to treatment. Twenty patients had received mastectomy and eighteen had received excisional biopsy plus radiation of the intact breast. Aside fro...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF01807591

    authors: Schain W,Edwards BK,Gorrell CR,de Moss EV,Lippman ME,Gerber LH,Lichter AS

    更新日期:1983-01-01 00:00:00

  • The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer.

    abstract:BACKGROUND:The aromatase inhibitors (AIs) are increasingly surpassing tamoxifen as the endocrine treatment of choice for postmenopausal breast cancer patients. With their increasing use, there is concern that they are being inadvertently prescribed to pre- and peri-menopausal women. METHODS:As part of a continuing med...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-9031-9

    authors: Gainford MC,McCready D,Clemons M

    更新日期:2006-04-01 00:00:00

  • GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.

    abstract:PURPOSE:Despite numerous studies on the utility of GATA-3 as breast cancer marker, its comparison with other breast markers, its concordance between primary and metastatic tumors and its expression in primary cancers from sites with frequent breast metastases remains unclear. METHODS:To address these questions, totall...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4645-2

    authors: Ni YB,Tsang JYS,Shao MM,Chan SK,Cheung SY,Tong J,To KF,Tse GM

    更新日期:2018-05-01 00:00:00

  • Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II.

    abstract::Findings from epidemiologic studies of oxidative stress biomarkers and breast cancer have been mixed, although no studies have focused on estrogen receptor-negative (ER-) tumors which may be more strongly associated with oxidative stress. We examined prediagnostic plasma fluorescent oxidation products (FlOP), a global...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3861-5

    authors: Hirko KA,Fortner RT,Hankinson SE,Wu T,Eliassen AH

    更新日期:2016-07-01 00:00:00

  • Followup after 11 years--update of mortality results in the Stockholm mammographic screening trial.

    abstract::Results from several randomised mammography screening trials have shown that it is possible to reduce mortality in breast cancer by mammographic screening at least for women above 50 years of age. The purpose of this article is to present data on mortality in breast cancer in study and control groups of the Stockholm ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1005872617944

    authors: Frisell J,Lidbrink E,Hellström L,Rutqvist LE

    更新日期:1997-09-01 00:00:00

  • Expression of pp32 gene family members in breast cancer.

    abstract::The pp32 gene family consists of at least three closely related members, pp32, pp32r1 and pp32r2. In spite of a high degree of identity at the nucleotide level, pp32 functionally behaves as a tumor suppressor where as pp32r1 and pp32r2 are pro-oncogenic. The purpose of this pilot study was to determine pp32-related ex...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1017919507109

    authors: Kadkol SS,El Naga GA,Brody JR,Bai J,Gusev Y,Dooley WC,Pasternack GR

    更新日期:2001-07-01 00:00:00

  • Data mining with decision trees for diagnosis of breast tumor in medical ultrasonic images.

    abstract::To increase the ability of ultrasonographic (US) technology for the differential diagnosis of solid breast tumors, we describe a novel computer-aided diagnosis (CADx) system using data mining with decision tree for classification of breast tumor to increase the levels of diagnostic confidence and to provide the immedi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1010676701382

    authors: Kuo WJ,Chang RF,Chen DR,Lee CC

    更新日期:2001-03-01 00:00:00

  • Estradiol enhances osteolytic lesions in mice inoculated with human estrogen receptor-negative MDA-231 breast cancer cells in vivo.

    abstract::The effect of 17-beta-estradiol (E2) on the induction of osteolytic lesions by estrogen receptor (ER)-negative breast cancer cells was investigated in 4-week-old female nude mice. Exposure to exogenous E2 was found to increase osteolytic areas on radiographs up to 5.3 times in mice inoculated intracardially with MDA-2...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1022943127689

    authors: Winding B,Misander H,Høegh-Andersen P,Brünner N,Foged NT

    更新日期:2003-03-01 00:00:00

  • Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).

    abstract:PURPOSE:We conducted an exploratory biomarker study from a phase II clinical trial of eribulin plus gemcitabine (EG) versus paclitaxel plus gemcitabine (PG) in HER2-negative metastatic breast cancer (BC) patients. METHODS:We performed targeted deep sequencing with a customized cancer gene panel and RNA expression assa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05400-y

    authors: Kim JY,Lee E,Park K,Im SA,Sohn J,Lee KS,Chae YS,Kim JH,Kim TY,Jung KH,Park YH,Breast Cancer Committee of the Korean Cancer Study Group.

    更新日期:2019-11-01 00:00:00

  • Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases.

    abstract::Circulating CA 15-3 antigen levels were evaluated in patients with benign diseases and breast cancer patients with no clinical evidence of disease after surgery (NED). Patients with breast cancer NED were followed for tumor recurrence or death during a median of 12.9 months (range 1 to 25 months). CA 15-3 and carcinoe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806524

    authors: Colomer R,Ruibal A,Genollá J,Rubio D,Del Campo JM,Bodi R,Salvador L

    更新日期:1989-03-01 00:00:00

  • Detection of multicentric and contralateral breast cancers on MRI based on primary cancer biomarker status: will this change surgical or medical management?

    abstract:PURPOSE:The utilization of staging preoperative breast MRI in biopsy-proven cancer patients varies based on institution and individual clinicians. It is unclear whether primary breast cancer subtype influences a clinician's decision to obtain a preoperative breast MRI based on likelihood of multicentric or contralatera...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4426-y

    authors: Jonna AR,Sam KQ,Ebuoma LO,Sedgwick EL,Wang T,Benveniste AP

    更新日期:2017-11-01 00:00:00

  • Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007).

    abstract::Bone lesions as a consequence of bone metastases in breast cancer patients can increase risk for skeletal-related events (SREs) (i.e., radiation to the bone, a pathological or osteoporotic fracture event, hypercalcemia, spinal cord compression, or surgery to the bone). The mortality risk for breast cancer patients wit...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1475-5

    authors: Yong M,Jensen AÖ,Jacobsen JB,Nørgaard M,Fryzek JP,Sørensen HT

    更新日期:2011-09-01 00:00:00